Toxic megacolon: Difference between revisions

(Prepared the page for translation)
(Add MedicationDose entry (hydrocortisone) with SMW annotations)
 
Line 85: Line 85:
**Nasogastric (NG) Tube NOT effective in reducing colonic distention
**Nasogastric (NG) Tube NOT effective in reducing colonic distention


==Medication Dosing==
{{MedicationDose
| drug = Hydrocortisone
| dose = 100mg q6hr
| route = IV
| context = Anti-inflammatory for underlying IBD
| indication = Toxic megacolon
| population = Adult
}}


==Disposition==
==Disposition==

Latest revision as of 18:55, 20 March 2026


Background

Average inner diameters and ranges of different sections of the large intestine.[1]
  • Colonic Dilation ≥6cm
  • Therapy: Fluids, Electrolyte Repletion, Steroids, Antibiotics, Surgical Consultation
  • AVOID anticholingerics, anti-motility agents, opioids


Causes


Clinical Features


Differential Diagnosis


Evaluation

Toxic megacolon on KUB
CT with toxic megacolon showing submucosal edema and mucosal enhancement of the ascending and descending colon giving the appearance of the “target sign”.
CT showing is diffuse dilation of the colon with air and fluid levels present. There is diffuse wall thickening and enhancement in the rectosigmoid colon. The descending, transverse, and ascending colon are dilated to as much as 8.5cm. These features are consistent with a diagnosis of toxic megacolon.


Management

  • Obtain blood cultures, stool cultures, C. Diff Toxin
  • If known cause is C. Diff treat with Vancomycin or Metronidazole
  • If known cause is CMV can add Ganciclovir
  • Avoid
    • Anticholinergics, anti-motility agents, opioids which can worsen dilation
    • Sulfasalazine or 5-aminosalicylate (5-ASA) unhelpful
    • Nasogastric (NG) Tube NOT effective in reducing colonic distention


Medication Dosing

Hydrocortisone 100mg q6hr IV

Disposition

  • Admit


See Also


References

  1. Nguyen H, Loustaunau C, Facista A, Ramsey L, Hassounah N, Taylor H, et al. (July 2010). "Deficient Pms2, ERCC1, Ku86, CcOI in field defects during progression to colon cancer". Journal of Visualized Experiments (41). doi:10.3791/1931. PMC 3149991. PMID 20689513.